ArticleFoods (Basel, Switzerland)2026
Sea Buckthorn Pericarp Flavonoids Improve Diet-Induced Hyperlipidemia via Coordinated Modulation of Hepatic Lipid Metabolism and Gut Microbiota.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sea buckthorn pericarp pomace, a major by-product of juice processing, represents a promising food-grade source of bioactive flavonoids. This study investigated the hypolipidemic effects and underlying mechanisms of total flavonoids extracted from Sea buckthorn pericarp pomace (TFSP) in mice with high-fat diet (HFD)-induced hyperlipidemia. TFSP intervention significantly suppressed body weight gain and improved serum lipid profiles by reducing total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), while increasing high-density lipoprotein cholesterol (HDL-C). Hepatic lipid accumulation and injury were alleviated, accompanied by enhanced activities of antioxidant enzymes (SOD, CAT, GSH-Px) and reduced oxidative stress markers. At the molecular level, TFSP downregulated key lipogenic proteins-including ACC and FAS-and upregulated markers of fatty acid oxidation and triglyceride hydrolysis-namely CPT-1α, PPARα, and ATGL. Moreover, TFSP restored HFD-induced gut microbiota dysbiosis, increased the relative abundance of beneficial genera such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.